No dramas at all Cortinaboy, I was wondering where you were with it. Given the stance with EMEA and FDA on the bronchiectasis front, I would seriously doubt the TGA on granting registration without the other planned Phase III study. Also, it is not as though our market will make it for this drug so I don't think the market would react poorly if the TGA held back till the other study is completed.
I think the Cystic Fibrosis results will be the most important driver in the short term. There should be a nice lead up in the SP prior to the results being released Q2 2009.
VVS
PXS Price at posting:
0.0¢ Sentiment: Hold Disclosure: Held
